阿瑞匹坦三联用药预防乳腺癌蒽环类药物联合环磷酰胺化疗致恶心呕吐的效果观察被引量：9

Clinical Observation of Aprepitant Triple Therapy on Prevention of Nausea and Vomiting Caused by Anthracycline Combined Cyclophosphamide Chemotherapy Regimen for Breast Cancer

下载PDF

导出

摘要目的评估阿瑞匹坦、托烷司琼、地塞米松三联方案预防乳腺癌蒽环类药物联合环磷酰胺化疗致恶心呕吐的效果及安全性。方法选择2014年1月—2015年6月沈阳军区总医院肿瘤科收治的接收蒽环类药物（表柔比星或多柔比星）联合环磷酰胺化疗的乳腺癌患者62例,根据预防化疗相关性恶心呕吐（chemotherapy-induced nausea and vomiting,CINV）方案的不同分为试验组和对照组各31例。两组常规化疗,对照组给予托烷司琼、地塞米松二联方案预防CINV,试验组在对照组治疗基础上加用阿瑞匹坦。观察两组化疗后急性期（0-24 h）及延迟期（24-120 h）预防恶心呕吐的效果及不良反应发生情况。结果化疗后呕吐急性期内两组CR率和有效控制率比较差异均无统计学意义（Z=-1.579,P=0.114）;呕吐延迟期内试验组CR率和有效控制率均高于对照组,差异均有统计学意义（Z=-2.196,P=0.028）。两组不良反应发生率比较差异无统计学意义（P〉0.05）,且不良反应均较轻微,患者可耐受。结论阿瑞匹坦三联方案对乳腺癌蒽环类药物联合环磷酰胺化疗致延迟性呕吐的疗效确切,且不良反应轻微,患者可耐受。 Objective To investigate the effect of combined therapy consisting of aprepitant,tropisetron and dexamethasone in prevention of nausea and vomiting induced by breast cancer chemotherapy based on anthracycline and cyclophosphamide. Methods A total of 62 cases of breast cancer collected from Oncology Department in General Hospital of Shenyang Military Area Command during January 2014 and June 2015 were selected,and those patients all underwent chemotherapy consisting of anthracycline（ epirubicin or doxorubicin） combined cyclophosphamide and they were divided into experimental group（ n = 31） and control group（ n = 31） by CINV（ chemotherapy-induced nausea and vomiting） regimen. The control group was given tropisetron and dexamethasone combined regimen in prevention of CINV while the experimental group was added with aprepitant based on the drug used by the control group. The effect and adverse reaction of two groups in acute phase（ 0-24 h） and delay period（ 24-120 h） on preventing nausea and vomiting were observed. Results The complete response rate and the control rate of acute phase had no statistical difference between the two groups（ Z =-1. 579,P = 0. 114）;however,for the delayed vomiting,the complete response rate and control rate of the experimental group were higher than that of the control group and there was significant statistical difference（ Z =-2. 196,P = 0. 028）. Adverse reactions were mild and tolerable with no significant differences between the 2 groups（ P〉0. 05）. Conclusion The combined therapy of aprepitant is definitely effective for the delayed vomiting induced by anthracycline combined cyclophosphamide chemotherapy regimen of breast cancer,and the toxic reaction is tolerable.

作者童雅兰韩涛宋树玺郑振东屈淑贤邱佳宁刘兆喆郭放谢晓冬

机构地区大连医科大学研究生院沈阳军区总医院全军肿瘤诊治中心肿瘤科

出处《临床误诊误治》 2016年第4期83-86,共4页 Clinical Misdiagnosis & Mistherapy

基金中国博士后科学基金面上项目(2015M582822)

关键词乳腺肿瘤阿瑞匹坦抗肿瘤联合化疗方案恶心呕吐 Breast neoplasm Aprepitant Antineoplastic combined chemotherapy protocol Nausea Vomiting

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献19

1Leonardi M C, Morra A, Santoro L, et al. Nonrandom- ized comparison between concomitant and sequential che- moradiotherapy with anthracyclines in breast cancer [ J ]. Tumori, 2015,101 ( 1 ) :64-71.
2Gralla R J, Osoba D, Kris M G, et al. Recommendations for the use of antiemetics: evidence-based, clinical prac- tice guidelines. American Society of Clinical Oncoiogy [J]. J Clin Oncol, 1999,17(9) :2971-2994.
3Jordan K, Schmoll H J, Aapro M S. Comparative activity of antiemetic drugs [ J ]. Crit Rev Oncol Hematol, 2007, 61(2) :162-175.
4Olver I, Clark-Snow R A, Ballatori E, et al. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential [ J ]. Support Care Cancer, 2011,19 ( Suppl 1 ) : S33-S36.
5Moradian S, Howell D. Prevention and management of chemotherapy-induced nausea and vomiting[ J]. Int J Pal- liat Nurs, 2015,21 (5) :216,218-224.
6Chan V T, Yeo W. Antiemetie therapy options for chem- otherapy-induced nausea and vomiting in breast cancer patients [ J ]. Breast Cancer ( Dove Med Press), 2011,3 : 151-160.
7Hesketh P J, Younger J, Sanz-Ahamira P, et al. Aprepi- rant as salvage antiemetic therapy in breast cancer pa- tients receiving doxorubicin and cyclophosphamide [ J]. Support Care Cancer, 2009,17 ( g ) : 1065-1070.
8Yeo W, Mo F K, Suen J J, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemo- therapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemo-therapy[ J]. Breast Cancer Res Treat, 2009, 113 ( 3 ) : 529-535.
9Dueck A C, Mendoza T R, Mitchell S A, et al. Validity and Reliability of the US National Cancer Institute "s Pa- tient-Reported Outcomes Version of the Common Termi- nology Criteria for Adverse Events (PRO-CTCAE) [ J ]. JAMA Oncol, 2015,1 (8) :1051-1059.
10陈敬华,申维玺,许瑞莲,夏俊贤,朱美琴,何婉,徐敏.阿瑞匹坦联合托烷司琼预防顺铂化疗引起呕吐的临床观察[J].中国药房,2014,25(26):2443-2446. 被引量：11

二级参考文献22

1Jordan K,Sippel C,Schmoll H J,et al.Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting:Past,Present,and Future Recommendations[J].Oncologist,2007,12 (9):1143-1150.
2Ballatori E,Roila F,Ruggeri B,et al.The impact of chemotherapy-induced nausea and vomiting on health-related quality of life[J].Supportive Care in Cancer,2007,15 (2):179-185.
3Grunberg S M,Deuson R R,Mavros P,et al.Incidence of chemotherapy-induced nausea and emesis after modern antiemetics?[J].Cancer,2004,100 (10):2261-2268.
4Aziz N M.Cancer survivorship research:State of knowledge,challenges and opportunities[J].Acta Oncol,2007,46 (4):417-432.
5Gralla R,Linchinister M,Vegt S V,et al.Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy:results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron[J]Ann Oncol,2003,14 (10):1570-1577.
6Eisenberg P,Figueroa-Vadillo J,Zamora R,et al.Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron,a pharmacologically novel 5-HT3 receptor antagonist[J].Cancer,2003,98 (11):2473-2482.
7Rapoport B L,Jordan K,Boice J A,et al.Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types:a randomized,double-blind study[J].Support Care Cancer,2010,18 (4):423-431.
8Hargreaves R.Imaging Substance P Receptors (NK1) in the Living Human Brain Using Positron Emission Tomography[J].J Clin Psychiatry,2002,63 (suppl 11):18-24.
9Cancer Therapy Evaluation Program.Common terminology criteria for adverse events v3.0(CTCAE),DCTD,NCI,NIH,DHHS[S].2003-03-31.
10Rojas C,Raje M,Tsukamoto T,et al.Molecular mechanisms of 5-HT(3)and NK(1)receptor antagonists in prevention of emesis[J].Eur J Pharmacol,2014(722):26.